kotak-logo
Lupin Share Price

Lupin Share Price

2343.8
+10.90 (0.47%)
LUPIN • 06 Mar, 2026 | 03:29 PM
Buywith MTF at 5x leverage

1Y Annualised Return

15.58%

3Y Annualised Return

52.12%

5Y Annualised Return

17.32%

10Y Annualised Return

2.49%

Lupin Stock Performance

1W Return1.82
1Y Return16.12
Today's Low2324.8
Prev. Close2,332.90
Mkt Cap (Cr.)1,07,121.79
1M Return7.83
3Y Return253.81
52-Week High2369.5
Open2,341.00
PE Ratio19.50
6M Return20.57
Today's High2369.5
52-Week Low1795.2
Face Value2

Lupin Company background

Founded in: 1983
Managing director: Nilesh Deshbandhu Gupta.

Lupin Limited is a top pharmaceutical company in India, globally recognized for its research and innovation orientation. It was established in 1968 by Dr. Desh Bandhu Gupta with a humble vision, which was to provide medicines at affordable prices to all and fulfill medical requirements that were not fulfilled. Lupin has become a worldwide giant over the years, manufacturing a broad array of drugs such as branded and generic medicines, biotechnology items, and essential ingredients used in the production of other drugs.

A Global Pharmaceutical Powerhouse

Lupin’s journey from a domestic-focused company to an internationally recognized pharmaceutical leader shows its relentless pursuit of excellence. The company operates in over 100 countries across North America, Europe, Asia-Pacific, and Africa. It’s headquartered in Mumbai, India. It has quite a strong presence in developed markets such as the United States, where it is among the top five generic pharmaceutical companies by prescriptions. Additionally, Lupin is a prominent player in emerging markets, catering to the healthcare needs of millions with high-quality and affordable medications.

Innovation has been one of the most important cornerstones of Lupin's growth strategy. The company has invested significantly in research and development (R&D), establishing many state-of-the-art facilities across the world. These R&D centers focus greatly on creating complex generics, biosimilars, and specialty products, demonstrating Lupin’s commitment to advancing healthcare solutions. Lupin’s prowess in R&D has led to a robust pipeline of products that address quite a few therapeutic areas, including cardiovascular diseases, respiratory ailments, central nervous system disorders, diabetes, and oncology.

Therapeutic Expertise

Lupin's wide-ranging product portfolio covers a fairly substantial number of therapeutic areas. It holds a leadership position in anti-tuberculosis treatments, reflecting its dedication to combating global health challenges. Also, the company has made great strides in therapies for cardiovascular health, diabetes management, respiratory conditions, and women’s health. Lupin has managed to solidify its reputation as a trusted partner in the pharmaceutical industry by aligning its products with the needs of not only patients but also healthcare providers.

Manufacturing Excellence

Lupin's production facilities are among the strongest forces behind its success. The organization has numerous top-notch production facilities approved by top regulatory bodies like the US FDA, UK MHRA, and WHO. All these facilities have a fair number of state-of-the-art technologies to produce medicines of high quality. Lupin's focus on upholding high-quality standards reflects its commitment towards providing safe and effective pharmaceutical drugs to markets all around the world.

Strategic Acquisitions and Partnerships

Lupin has strategically expanded its reach and capabilities through acquisitions and partnerships. The acquisition of Gavis Pharmaceuticals and Novel Laboratories in the United States marked a great milestone in strengthening Lupin’s position in the world’s largest pharmaceutical market. The company’s partnerships with global pharmaceutical leaders have also enabled it to enhance its product offerings and cater to unmet medical needs.

Commitment to Sustainability

Other than its business activities, Lupin is greatly dedicated to corporate social responsibility and sustainable practices. Also, the firm is actively engaged in minimizing its environmental impact through green initiatives and optimal use of resources. Lupin's philanthropic organization, the Lupin Human Welfare and Research Foundation (LHWRF), has played a great role in empowering underprivileged society by focusing on healthcare, education, and skill development initiatives.

Financial Performance and Market Presence

Lupin has consistently delivered robust financial performance, driven by its diversified product portfolio, geographic expansion, and operational efficiency. The company’s ability to adapt to evolving market dynamics has also allowed it to maintain quite a competitive edge in the global pharmaceutical space. Investors often monitor Lupin share price as a barometer of the company’s market strength as well as its future prospects.

Brief Overview

While Lupin continues on its growth and innovation journey, it is always extremely committed to tackling new healthcare issues that emerge. The company is actively exploring new therapeutic areas, leveraging digital technologies, and enhancing its R&D capabilities to deliver breakthrough solutions. By staying true to its founding principles and embracing a forward-looking approach, Lupin aims to create a lasting impact on global healthcare.

Lupin Limited’s story is one of resilience, innovation, and commitment to improving lives. From its humble beginnings to becoming a global pharmaceutical powerhouse, Lupin has consistently demonstrated its ability to adapt and thrive in a dynamic industry. With its unwavering focus on quality, sustainability, and patient-centric solutions, Lupin is well-positioned to lead the future of healthcare innovation.

Lupin Financial Highlights


For the full year FY2025–2026, revenue reached ₹22903.72 crore and profit touched at ₹3306.26 crore. As of Dec '25, Lupin’s market capitalisation stood at ₹1,07,121.79 crores. Shareholding as of Dec '25 shows promoters holding 46.9%, with FIIs at 21.5%, DIIs at 25.6%, and public at 6%.

Lupin Share Price Today


As of 7 Mar 2026, Lupin share price is ₹2343.8. The stock opened at ₹2341 and had closed at ₹2332.9 the previous day. During today’s trading session, Lupin share price moved between ₹2,324.80 and ₹2,369.50, with an average price for the day of ₹2347.15. Over the last 52 weeks, the stock has recorded a low of ₹1,795.20 and a high of ₹2,369.50. In terms of performance, Lupin share price has increased by 20.6% over the past six months and has increased by 15.58% over the last year.
Read More
Lupin SIP Return Calculator
5,000
Over the past
Total Investment of ₹3,00,000
Monthly SIP of 5,000 would have become 4,78,884 in 5 years with a gain of 1,78,884 (+59.63%)
View details of Market Depth

Lupin Fundamental

Market Cap (in crs)

1,07,121.79

Face Value

2

Turnover (in lacs)

32,207.21

Key Metrics

Qtr Change %
New 52W High today
11.7
Dividend yield 1yr %
Below industry Median
0.5

Lupin Key Financials

View more
Loading chart...
Lupin Quarterly Revenue
Lupin Yearly Revenue
Lupin Quarterly Net Profit/Loss
Lupin Yearly Net Profit/Loss

Lupin Result Highlights

  • Lupin Ltd reported a 2.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 25.1%.

  • Its expenses for the quarter were up by 4.0% QoQ and 12.3% YoY.

  • The net profit decreased 20.5% QoQ and increased 37.5% YoY.

  • The earnings per share (EPS) of Lupin Ltd stood at 25.67 during Q3 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lupin Technical Analysis

Moving Averages Analysis
2343.8
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
Day EMA5
2,320.90
Day EMA10
2,297.40
Day EMA12
2,289.30
Day EMA20
2,262.70
Day EMA26
2,247.00
Day EMA50
2,199.80
Day EMA100
2,136.70
Day EMA200
2,075.90
Delivery & Volume
Loading chart...

Day

63.60%

Week

62.50%

Month

54.30%

Delivery & Volume

2,346.03
Pivot
Resistance
First Resistance
2,367.27
Second Resistance
2,390.73
Third Resistance
2,411.97
Support
First Support
2,322.57
Second support
2,301.33
Third Support
2,277.87
Relative Strength Index
71.29
Money Flow Index
68.13
MACD
42.28
MACD Signal
34.72
Average True Range
46.57
Average Directional Index
20.07
Rate of Change (21)
6.77
Rate of Change (125)
20.86
Compare

Lupin Shareholding Pattern

Promoter
46.9%
Foreign Institutions
21.5%
Mutual Funds
18%
Domestic Institutions
25.6%
Public
6%

Lupin Latest News

06 MAR 2026 | Friday
02 MAR 2026 | Monday
27 FEB 2026 | Friday

Please be aware that Lupin stock prices are subject to continuous fluctuations due to various factors.